Gilead Sciences(us:GILD)
111.77
-0.02%
Updated on 2025-03-31
Open:109.67
Close:111.77
High:112.46
Low:109.60
Prev Close:111.79
Volume:8.83M
Turnover:985.65M
Turnover Ratio:0.71%
Shares:1.25B
MarketCap:139.34B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 1764 | 1034110742 | 82.99% | 125 | 627 | 808 |
| 2024-03-31 | 1805 | 1019637169 | 81.83% | 120 | 616 | 866 |
| 2023-12-31 | 1809 | 1038972236 | 83.38% | 202 | 638 | 775 |
| 2023-09-30 | 1736 | 1019838625 | 81.78% | 124 | 664 | 726 |
| 2023-06-30 | 1753 | 1022732324 | 81.99% | 99 | 612 | 818 |
| 2023-03-31 | 1762 | 1016219313 | 81.43% | 110 | 641 | 793 |
| 2022-12-31 | 1802 | 1024751393 | 82.18% | 271 | 545 | 814 |
| 2022-09-30 | 1634 | 987401882 | 78.74% | 99 | 718 | 613 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Blackrock Inc. | 120632023 | 9.68% | -1899004 | -1.55% |
| 2024-06-30 | Vanguard Group Inc | 115261774 | 9.25% | 529199 | 0.46% |
| 2024-06-30 | Capital World Investors | 76249819 | 6.12% | -8247585 | -9.76% |
| 2024-06-30 | Capital Research Global Investors | 60427714 | 4.85% | -818652 | -1.34% |
| 2024-06-30 | State Street Corp | 59329915 | 4.76% | 1624987 | 2.82% |
| 2024-06-30 | Dodge & Cox | 33122337 | 2.66% | -45150 | -0.14% |
| 2024-06-30 | Geode Capital Management, Llc | 26966449 | 2.16% | 617094 | 2.34% |
| 2024-06-30 | Wellington Management Group Llp | 22935083 | 1.84% | 2367331 | 11.51% |
| 2024-06-30 | Morgan Stanley | 19337304 | 1.55% | 1323720 | 7.35% |
| 2024-06-30 | Fmr Llc | 18482158 | 1.48% | 893636 | 5.08% |
About
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Address:333 Lakeside Drive
Website:http://www.gilead.com
Market Movers